CD4 and neoplasm: We have previously shown that sunitinib temporarily relieves the immunosuppression of sunitinib-naїve patients [15], and the present findings confirm that the drug's efficacy parallels the appearance of a signature consisting of activated tumour-infiltrating lymphocytes (TILs), including CD3+, CD4+ and CD8+ cells, and CD68+ myeloid cells [15].